NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $112.37 +1.60 (+1.44%) Closing price 04/3/2025 03:59 PM EasternExtended Trading$108.61 -3.76 (-3.35%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$112.26▼$114.4450-Day Range$99.93▼$115.6052-Week Range$92.35▼$120.92Volume2.93 million shsAverage Volume1.51 million shsMarket Capitalization$229.68 billionP/E Ratio19.11Dividend Yield2.23%Price Target$123.38Consensus RatingReduce Company OverviewNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More… Remove Ads Novartis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 44% of companies evaluated by MarketBeat, and ranked 598th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingReduce Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.26% Earnings GrowthEarnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 19.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.62.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 19.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.23.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.70. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 20.24%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.26%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 42.69%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 28.49% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently decreased by 20.24%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment0.95 News SentimentNovartis has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Novartis this week, compared to 14 articles on an average week.Search Interest12 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows11 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesNovartis price target raised to CHF 115 from CHF 110 at Deutsche BankApril 4 at 6:50 AM | markets.businessinsider.comDeutsche Bank Remains a Buy on Novartis AG (NOVN)April 4 at 1:49 AM | theglobeandmail.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 4, 2025 | Golden Portfolio (Ad)Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)April 4 at 1:49 AM | theglobeandmail.comNovartis gets FDA accelerated approval for kidney disease treatmentApril 3 at 8:49 PM | msn.comNovartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug ApprovalApril 3 at 10:02 AM | investors.comNovartis gets FDA accelerated approval for VanrafiaApril 3 at 4:21 AM | markets.businessinsider.comNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)April 2 at 8:29 PM | prnewswire.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $97.31 at the start of the year. Since then, NVS stock has increased by 15.5% and is now trading at $112.37. View the best growth stocks for 2025 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its earnings results on Friday, January, 31st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a trailing twelve-month return on equity of 37.24%. Does Novartis have any subsidiaries? Novartis subsidiaries include Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. Who are Novartis' major shareholders? Top institutional shareholders of Novartis include Boston Common Asset Management LLC (0.01%), First Hawaiian Bank, Park National Corp OH and Versant Capital Management Inc. How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK). Company Calendar Last Earnings1/31/2025Record date for 3/12 Dividend3/12/2025Ex-Dividend for 3/12 Dividend3/12/2025Dividend Payable3/12/2025Today4/03/2025Next Earnings (Estimated)4/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees101,700Year Founded1996Price Target and Rating Average Stock Price Target$123.38 High Stock Price Target$130.00 Low Stock Price Target$120.00 Potential Upside/Downside+9.8%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$5.88 Trailing P/E Ratio19.11 Forward P/E Ratio13.30 P/E Growth1.7Net Income$11.94 billion Net Margins23.56% Pretax Margin26.37% Return on Equity37.24% Return on Assets15.85% Debt Debt-to-Equity Ratio0.48 Current Ratio1.04 Quick Ratio0.84 Sales & Book Value Annual Sales$51.72 billion Price / Sales4.44 Cash Flow$11.20 per share Price / Cash Flow10.03 Book Value$21.59 per share Price / Book5.20Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$229.68 billion OptionableOptionable Beta0.56 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:NVS) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NVS Stock Free NVS Stock Alerts